10x Genomics, Inc. Q3 2025 Earnings Recap

TXG Q3 2025 November 7, 2025

Get alerts when TXG reports next quarter

10X Genomics reported a solid third quarter, exceeding revenue expectations with $149 million driven by strong demand for both single-cell and spatial biology products despite ongoing macroeconomic challenges.

Earnings Per Share Miss

$-0.22 vs $-0.07 est.

-214.3% surprise

Revenue Beat

149002000 vs 142499900 est.

+4.6% surprise

Market Reaction

1-Day +12.0%

5-Day +4.2%

30-Day +14.95%

See TXG alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue of $149 million surpassed guidance, reflecting strong execution amid macro pressures.
Significant year-over-year growth in spatial consumables, particularly for Xenium, continued to drive momentum.
Expansion of product offerings, including new Chromium Flex and Xenium protein, is anticipated to enhance market adoption and streamline workflows.
Ended the quarter with a robust $482 million cash position, ensuring flexibility for strategic investments.
Customer sentiment indicates sustained cautious spending behavior, particularly concerning capital expenditures.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TXG on AllInvestView.

Next Q1 2026